dc.contributor.author | Cho, K. H. | en |
dc.contributor.author | Pezzuto, J. M. | en |
dc.contributor.author | Bolton, J. L. | en |
dc.contributor.author | Steele, V. E. | en |
dc.contributor.author | Kelloff, G. J. | en |
dc.contributor.author | Lee, S. K. | en |
dc.contributor.author | Constantinou, Andreas I. | en |
dc.creator | Cho, K. H. | en |
dc.creator | Pezzuto, J. M. | en |
dc.creator | Bolton, J. L. | en |
dc.creator | Steele, V. E. | en |
dc.creator | Kelloff, G. J. | en |
dc.creator | Lee, S. K. | en |
dc.creator | Constantinou, Andreas I. | en |
dc.date.accessioned | 2019-11-04T12:50:20Z | |
dc.date.available | 2019-11-04T12:50:20Z | |
dc.date.issued | 2000 | |
dc.identifier.uri | http://gnosis.library.ucy.ac.cy/handle/7/52977 | |
dc.description.abstract | The present study was undertaken to determine if in vitro inhibition of one or both of the two most dominant mammalian DNA topoisomerases (topos) is common among chemopreventive agents. To determine if an agent was a topo I inhibitor, we employed the DNA relaxation and nicking assays. For potential topo II inhibitors, we used the DNA unknotting and linearisation assays. 14 of 30 agents (47%) were ineffective in all four assays (IC50 >100 μg/ml), and 11 (37%) inhibited topo II catalytic activity. The sensitivity of the topo II assay was 63%, selectivity 93%, positive predictive value 91%, and total accuracy 77%. For chemopreventive efficacy, the positive predictive value of the unknotting assay was 92%, and the total accuracy was 60%. These data suggest that reduced topo II activity is a desirable property of many known chemopreventive agents. We conclude that the unknotting assay could be a valuable addition to the in vitro tests presently used to select chemopreventive agents. Copyright (C) 2000 Elsevier Science Ltd. | en |
dc.source | European journal of cancer | en |
dc.source.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-0033810964&doi=10.1016%2fS0959-8049%2800%2900300-2&partnerID=40&md5=e9fd0e2e76dfd25bbf5d89e49b498baa | |
dc.subject | article | en |
dc.subject | antineoplastic agent | en |
dc.subject | human | en |
dc.subject | Neoplasms | en |
dc.subject | controlled study | en |
dc.subject | female | en |
dc.subject | prediction | en |
dc.subject | priority journal | en |
dc.subject | male | en |
dc.subject | unclassified drug | en |
dc.subject | Anticarcinogenic Agents | en |
dc.subject | Chemoprevention | en |
dc.subject | nonhuman | en |
dc.subject | DNA topoisomerase inhibitor | en |
dc.subject | drug selectivity | en |
dc.subject | drug screening | en |
dc.subject | Mice | en |
dc.subject | Animal | en |
dc.subject | animal model | en |
dc.subject | mouse | en |
dc.subject | DNA | en |
dc.subject | DNA topoisomerase (ATP hydrolysing) | en |
dc.subject | Topoisomerase I | en |
dc.subject | chemoprophylaxis | en |
dc.subject | Sensitivity and Specificity | en |
dc.subject | Predictive value | en |
dc.subject | accuracy | en |
dc.subject | enzyme inhibition | en |
dc.subject | catalysis | en |
dc.subject | Support, Non-U.S. Gov't | en |
dc.subject | DNA Topoisomerases, Type II | en |
dc.subject | Support, U.S. Gov't, P.H.S. | en |
dc.subject | genistein | en |
dc.subject | caffeic acid derivative | en |
dc.subject | gallic acid | en |
dc.subject | rat | en |
dc.subject | Rats | en |
dc.subject | 1,2 dithiole 3 thione derivative | en |
dc.subject | 1,4 phenylene bis(methylene)selenocyanate | en |
dc.subject | 3 indolemethanol | en |
dc.subject | 4 aminobutyric acid | en |
dc.subject | 4 hydroxy 2 ethyl 5 methyl 3(2h) furanone | en |
dc.subject | anethole trithione | en |
dc.subject | ascorbigen | en |
dc.subject | assay | en |
dc.subject | astaxanthin | en |
dc.subject | caffeic acid phenethyl ester | en |
dc.subject | Carcinogenesis | en |
dc.subject | chalcone | en |
dc.subject | chemical carcinogenesis | en |
dc.subject | diflunisal | en |
dc.subject | DNA topoisomerase | en |
dc.subject | DNA Topoisomerases, Type I | en |
dc.subject | Drug Screening Assays, Antitumor | en |
dc.subject | drug specificity | en |
dc.subject | ellagic acid | en |
dc.subject | galanin | en |
dc.subject | Hamsters | en |
dc.subject | hederagenin | en |
dc.subject | madecassoside | en |
dc.subject | maltol | en |
dc.subject | nifedipine | en |
dc.subject | oleanolic acid | en |
dc.subject | Organoselenium | en |
dc.subject | piroxicam | en |
dc.subject | protamine sulfate | en |
dc.subject | protocatechuic acid | en |
dc.subject | quercetin | en |
dc.subject | Relaxation assay | en |
dc.subject | resveratrol | en |
dc.subject | s allylcysteine | en |
dc.subject | Selectivity | en |
dc.subject | Specificity | en |
dc.subject | sphingomyelin | en |
dc.subject | sulphoraphane | en |
dc.subject | thiaproline | en |
dc.subject | Topoisomerase II | en |
dc.subject | Unknotting assay | en |
dc.subject | ursolic acid | en |
dc.title | Selection of cancer chemopreventive agents based on inhibition of topoisomerase II activity | en |
dc.type | info:eu-repo/semantics/article | |
dc.identifier.doi | 10.1016/S0959-8049(00)00300-2 | |
dc.description.volume | 36 | |
dc.description.startingpage | 2146 | |
dc.description.endingpage | 2156 | |
dc.author.faculty | Σχολή Θετικών και Εφαρμοσμένων Επιστημών / Faculty of Pure and Applied Sciences | |
dc.author.department | Τμήμα Βιολογικών Επιστημών / Department of Biological Sciences | |
dc.type.uhtype | Article | en |
dc.description.notes | <p>Manufacturers: Sigma, United States | en |
dc.description.notes | Cited By :39</p> | en |
dc.source.abbreviation | Eur.J.Cancer | en |
dc.contributor.orcid | Constantinou, Andreas I. [0000-0003-0365-1821] | |
dc.gnosis.orcid | 0000-0003-0365-1821 | |